COMPANY PROFILE

Etiome

Explore full profile

Biostaged Medicines targeting disease progression with stage-specific therapies for improved health outcomes

Cambridge, United StatesFounded 2021Biotech & Life Sciences

Valuation $250–500M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Etiome

Etiome operates in the healthcare sector, focusing on the development of preemptive medicines aimed at altering the course of diseases before they become debilitating. The company leverages detailed biological models to create Biostaged Medicines, which are stage-specific therapies designed to be delivered to the right patient population at the optimal time. This approach aims to slow, stop, or prevent the damage and discomfort caused by diseases. Etiome's business model revolves around the research and development of these therapies, targeting healthcare providers and patients seeking advanced treatment options. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of their therapeutic solutions. The company is part of the Flagship Pioneering portfolio, which has a history of launching successful therapeutic platforms.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: Cambridge, United States
Employees: 23
Open positions: None listed
Dealroom signal: 92.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Genetics and genomics, Biotech and Pharma, AI Drug Discovery, DT and LS
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Apr 2025	$50M	$200M	Flagship Pioneering	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Etiome website traffic

Latest recorded traffic for Etiome is 1.7K monthly website visits, down 58.5% over the last three months. Etiome's team grew 2200% over the past year.

Latest monthly visits1.7K 3-month web change-58.5% 1-year team growth+2200%

Monthly website visitsNov 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PBProxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation	New York City, United States	Operational	77	$80M	$320M
NANorVita Med AsPatient-derived organoid and neuron models for drug discovery and precision medicine in mitochondrial disease therapy	—	Operational
DLDante LabsGenomic and precision medicine solutions, from whole genome sequencing and interpretation to data-driven drug discovery	Hendersonville, United States	Operational
PBPrecision BioPharmaPioneering drug development with AI-driven Adaptive Translational Research for rapid discovery and regulatory success	Stockholm, United States	Operational
SBSidera BioAdvancing genetic discoveries to enhance precision medicine through large-scale data analyses	Cambridge, United States	Operational
XBXanadu BioPioneering cystic fibrosis treatment through small molecules and gene editing	Lower Merion Township, United States	Operational
PTParadigm TherapeuticsBiopharmaceutical solutions for Epidermolysis Bullosa, offering comprehensive topical treatments for all subtypes	Mount Pleasant, United States	Operational
RBRadical BioHigh-resolution mass spectrometry for precise disease-specific protein structure analysis in drug discovery	Madison, United States	Operational